Adequacy of dialysis: A critical analysis  by Vanholder, Raymond C. & Ringoir, Severin M.
Kidney International, Vol. 42 (1992), pp. 540—558
EDITORIAL REVIEW
Adequacy of dialysis: A critical analysis
The "uremic syndrome" closely resembles systemic poison-
ing, with multiple symptoms and side effects [1—3]. Survival is
possible only when toxins are eliminated, which first became
possible with hemodialysis. Survival quality depends on the
quantity of toxins which are eliminated. There is a compelling
demand for objective definitions of the adequacy of this dialy-
sis: how much removal in how much time is necessary for each
individual? The answer has often been indirect and approxi-
mate.
Adequacy is derived from the Latin adaequare: to equalize.
The question is: equal to what? The only acceptable gold
standard is to clean blood and biological fluids to a degree
comparable with normal renal function.
Our insight and success with the correct definition and
realization of adequate dialysis is hampered by: (1) the use of
markers that are non-toxic, or non-representative for large
groups of toxins; (2) the technical limitations of dialysis; (3) the
limited accuracy of the usual parameters of dialysis perfor-
mance; (4) the changing concepts and definitions of "adequate
dialysis."
Some may define adequacy of dialysis as a determination
made by clinical assessment of patient well-being. Experience
has taught, however, how inadequate dialysis may be over-
looked by strictly adhering to clinical criteria, although the
inverse is equally true. The problem cannot be detached from
economic considerations, nor from the complex interaction
between the dialysis procedure and material on the one hand,
and the patient on the other [3, 4].
It is our goal in this editorial to review all the aspects of
adequacy of hemodialysis and to analyze its pitfalls. Future
trends should become evident.
Uremic toxicity
The quest for adequate dialysis is overshadowed by the lack
of definition of uremic toxicity. The attenuation of uremic
symptoms by the restriction of dietary protein and by dialysis
underscores the role of retention, removal and metabolism in
the uj-emic syndrome, but our knowledge on pathophysiology
remains fragmentary [2]. The discussion of "the" uremic toxin
is an oversimplification. Toxicity may result from the synergism
of the entire spectrum of accumulated components (Table 1).
Many solutes exert in vitro effects, but their responsibility in
vivo is more difficult to establish. Aspecific removal eliminates
essential compounds together with potential toxins. A more
correct outline of the essentials of uremic toxicity is thus
indispensable for delineating exactly how dialysis should be
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performed adequately. In the meantime we have to rely on
indirect estimates, so-called markers.
Solute concentration
Solute related factors
The relevant solute concentration with regard to dialyzer
transport is the free concentration in plasma water (Table 2).
Protein binding reduces efficiency of removal [5]. Intra-dialysis
protein binding changes with blood pH and with protein and
solute concentration, and depends on ultrafiltration, dialysate
buffer, and competition at the binding sites with other ligands
(uremic toxins, metabolites and drugs). At 100% binding
dialytic elimination is reduced to zero [6, 7].
The larger the distribution volume, the smaller the interdia-
lytic and intradialytic concentration changes, for the same
clearance and generation (Fig. 1). With multicompartmental
distribution, resistance for solute transfer from cells or tissues
to plasma will inhibit removal [8]. Elimination from the blood
may be excellent, whereas intra-cellular concentration remains
unaltered [91. Other factors may influence trans-cellular shifts,
for example, the movement of K into or out of the cells,
depending on blood pH.
Patient related factors
Solute accumulation is proportional to generation, after me-
tabolization of exogenous or endogenous precursors. Removal
by residual renal function becomes more critical with a low
and/or inadequate intradialytic removal [10, 111 (Fig. 2).
Access quality may play a role as an important factor, but will
be discussed more in detail later (see Assessment of Adequacy).
A rise in hematocrit may decrease mass transfer [12, 13] due
to blood viscosity [14]. Erythropoietin may thus have a negative
influence on dialysis adequacy by its effect on hematocrit
[15—18]. Objective assessment, such as by kinetic analysis, then
becomes germane, as clinical signs of uremia, such as fatigue,
are masked [15].
Dialysis related factors
The most important resource of dialysis efficiency is the
delivery of solute by blood flow. The relation between blood
flow and clearance reaches a plateau once clearance becomes
surface dependent [19, 20]. This occurs sooner with higher
molecular weight (Fig. 3A) [21]. Effective blood flows are often
lower than pursued, due to operator error, nonocciusive
pumps, malposition of the vascular access needle, access
failure, tubing diameter changes, temperature, and shear effects
[22—23].
Mass transfer is dialysate flow and concentration gradient
dependent. The curve flattens for higher flows (Fig. 3B).
Dialysate recirculation will reduce the concentration gradient
and hence removal.
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Table 1. Uremic solutes with potential toxicity Table 2. Factors influencing solute concentration in dialyzed patients
Urea Solute related factors
Guanidines Compartmental distribution
Methylguanidine Intracellular concentration
Guanidine Resistance of cell membrane
13-guanidinopropionic acid Protein bindingGuanidinosuccinic acid Electrostatic chargeGamma-guanidinobutyric acid Steric configuration
Taurocyamine Molecular weightCreatinine
Creatine Patient related factors
Arginic acid Distribution volume and body weight
Homoarginine Intake and generation
N-a-acetylarginine Solute
Phenols Metabolic precursors0-cresol Residual renal functionP-cresol Access quality
Benzylalcohol Absorption from the intestinePhenol HematocritTyrosine Blood viscosityPhenolic acids
P-hydroxyphenylacetic acid Dialysis related factors
13-(m-hydroxyphenyl)-hydracrylic acid Dialysis time
Hippurates Interdialytic intervals
P-(OH)hippuric acid Blood flow
O-(OH)hippuric acid Mean blood flow
Hippuric acid Blood flow patternBenzoates Concentration gradientPolypeptides
/32-microglobulin Dialysate flow
Indoles Dialyzer surface
Indol-3-acetic acid Dialyzer volume
Indoxyl sulfate Dialyzer membrane resistance
5-Hydroxyindol acetic acid Dialyzer pore size
Lndol-3-acrylic acid Adsorption
5-Hydroxytryptophol On the membrane
N-acetyltryptophan On other constituents of the circuit
Tryptophan Ultrafiltration rate
Middle moleclues Intra-dialytic changes in efficacy
Ammonia Changes with indirect effect on solute related factors
Alkaloids Blood pH
Trace metals (bromine a.o.) HeparinizationUric acid Free fatty acid concentration
Cyclic AMP
Amino acids
Myoinositol
Mannitol
Oxalate Dialyzer surface and volume influence solute elimination,Glucuronate
Glycols especially at higher blood flows. Volume may change due to
Lysozyme events not directly related to the dialyzer structure per Se, such
Hormones as clotting and protein clogging. Clotting and clogging at theParathormone
Natriuretic factor hydrophobic surfaces and pores may also decrease filtration
Glucagon and sieving coefficients [24, 25].
Growth hormone Membrane resistance is related to the chemical composition,
Gastnn electrostatic charge, interface free energy, surface hydropho-Prolactin
Catecholamines bicity or hydrophilicity, thickness, pore size of the membrane
Xanthine and/or protein accumulation on the membrane. Differences in
Hypoxanthine hydrophilic distribution (mosaicism) may alter transport pat-Furanpropionic acid terns. Fluid layers in the direct proximity of the membraneAmines
Putrescine create extra resistance (channeling) [14, 26]. Lower blood and
Spermine dialysate flows will decrease "fluid mixing" which increases
Spermidine film resistance for the small molecules [19]. The sieving effect of
Dimethylamine
Polyamines membranes follows an S-shaped curve around the cut-off,
Endorphins depending on pore size [23]. The slope of the straight section
Pseudouridine depends on the scatter of pore size. Dialyzer geometry influ-
Potassium
Phosphorus ences adequacy. Overall resistance to transfer is higher and
Calcium more variable in parallel plate than in capillary dialyzers [271,
Sodium due to membrane stretching, increasing blood-film thickness
Water and resistance, and to support masking of the membrane,
Cyanides especially at high transmembrane pressures.
Pre- Post- Time
dialysis dialysis
Fig. 1. Concentration pattern of a fully water-distributed solute in two
patients with a distribution volume of 44.9 (• •) and 28.2 liters(O 0), respectively. Generation rate was 10 mg/mm and dialyzer
clearance was 188 mI/mm in both cases. The concentration shifts are
more important in the patient with the smaller distribution volume.
A significant alteration of concentration of several solutes by
adsorption has been demonstrated [28—30], which may be offset
by reuse [31, 32].
Solute elimination increases with dialysis time, as long as
solute remains available in the vascular compartment. A high
cellular transmembrane resistance inhibits removal, except
when frequent, short dialyses are performed. The interdialytic
time interval thus influences solute concentration ( 'unphysiol-
ogy" of intermittent dialysis) [33—35].
Buffer composition of dialysate and substitution fluid may
influence acid-base balance, clinical tolerance and amount of
dialysis [36].
Backfiltration/backdiffusion is the process whereby dialysate
enters the blood stream through interference of osmotic and
concentration gradients, which depends on path length and
pressure drop along the dialyzer. Dialysate contents, such as
endotoxin, pesticides or insecticides, may enter the blood-
stream this way [37—39], except when they are adsorbed at the
dialysate side of the membrane.
Ultrafiltration depends on transmembrane pressure (blood
side minus dialysate and colloid osmotic pressure), membrane
permeability and blood dilution [3, 23, 40], and is over a wide
range correlated to blood flow [41]. It increases dialysance of
the larger solutes [2, 23, 42—45], but diminishes diffusive clear-
ance [46, 47], and indirectly diminishes adequacy by its asso-
ciation to hypotensive dialysis interruptions [48]. It is a cause of
increase of blood solute concentration when transmembrane
transfer is zero, as is the case for 32-microglobulin with small
pore dialyzers. Correction for this ultrafiltration effect may
disclose that there is no net change in body pooi [31, 49].
Conclusion
The factors affecting solute concentration in dialyzed patients
are abundant. They are different from solute to solute, and for
a given solute each minute detail in the dialysis approach may
further cause differences in concentration behavior. The pre-
Dialyzer clearance, mi/mm
Fig. 2. Percentage of total clearance delivered by residual renal clear-
ance (KR) in function of dialyzer clearance, for 3 * 4 hrs dialysis per
week. Symbols are: (•) KR 10 ml/min; (4) KR 7.5 mI/mm; (*) KR 5
mI/mm; (U) KR 3 mllmin; (A) KR 2 mI/mm; (•) KR I mi/mm. The
contribution of KR is related inversely to dialyzer clearance and is
especially important for the lower dialyzer clearances.
diction of concentration changes of other solutes by the evolu-
tion of a given marker, may therefore be difficult. Further,
biochemical toxicity may be related to extracellular as well as to
intramembrane and intracellular solute concentrations, where
emphasis has primarily been up to now on blood and serum
concentrations.
Assessment of adequacy
Clinical parameters
Subjective complaints and objective clinical findings (Table 3)
are useful parameters of dialysis adequacy and/or uremic tox-
icity, but may as well be affected by non-uremic causes and
medical treatment. When conventional clinical investigations
turn out to be insufficient, more sophisticated procedures, such
as electromyography [50], electroencephalography [51—54] and
neuropsychologic tests [55], may offer the only way to early
perception. Detection of underdialysis by clinical parameters
depends on awareness and frequency of control; the risk that
underdialysis is overlooked is substantial. Inadequate therapy
can remain unrecognized when therapeutic decisions are exclu-
sively based on clinical parameters [56]. Nevertheless, the
inverse is as true, and follow-up of dialysis adequacy should
never be restricted to static or dynamic biochemical parameters
(solute concentration, clearance, kinetic modeling and the like).
When estimating adequacy, clinical signs of underdialysis
should never be ignored.
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Fig. 3. In vitro dialyzer clearance
(cuprophane 0.8 m2) in function of dialyzer
blood compartment blood flow (A dialysate
flow 500 mi/mm) and in function of dialysate
flow (B blood flow: 200 mI/mm) for urea(circles, molecular wt 60D), creatinine
(triangles, molecular wt 113D) and hippuric
acid (squares, molecular wt 179D). Clearance
increases in function of blood and dialysate
flow, but tends to reach a plateau at the
higher flows, especially for hippuric acid, the
solute with the highest molecular wt (modified
from the Doctoral Thesis by P Pieters, ref 21;
used with permission).
Patient morbidity
Toxicity or underdialysis ultimately causes illness. Hospital-
ization rate is a current index of dialysis inadequacy [57, 58].
More than 25% of all hospitalizations is due to access problems
[58, 59] that are sometimes excluded from this assessment [601.
Comparison among centers or standardization of this parameter
may be difficult, however, because of differences in local
conditions for admission.
Assessment of quality of life
The perception of disease [61], assessed by patients, doctors,
nurses, or social workers, necessitates a strict translation of
subjective impressions into objective parameters. One problem
is the misjudgment of patient condition by patients themselves
[51, 62, 63] or by those delivering patient care [51].
Numerous patients undergoing dialysis do not work or func-
tion as the healthy population [62], and their physical activity
and employment status is not beyond the level of taking care of
themselves [64]. The best patients in hemodialysis are often
selected for transplantation. Parfrey et al found a major im-
provement of quality of life of dialyzed patients, following
transplantation [65], but no attention was paid to the quality or
quantity of the dialysis delivered.
Mortality
Mortality among end-stage renal patients is higher than in the
general population [66]. Secondary factors, such as race, vol-
untary withdrawal, age, and various diseases (mainly diabetes
and cardiovascular) interfere with survival on dialysis [65,
67—72]. Selection criteria for acceptance in dialysis and atti-
tudes towards renal transplantation play a role [731: in Japan,
where survival on dialysis is better than in any other country,
the number of patients treated with transplantation is very low.
A neglected factor is the moment to start dialysis [73].
Kjellstrand et al have suggested that there is an increase of
morbidity and mortality when dialysis is started late [33, 34].
The current trend to restrict protein in pre-end-stage renal
disease may reduce subjective complaints and postpone the
start of dialysis, but will not necessarily improve overall out-
come, especially as protein restriction per se may increase
morbidity on dialysis [74].
Biochemical evaluation
Static biochemical tests. Single "static" evaluations (Table
4) are influenced by other factors than dialysis adequacy as
well. When protein intake is deficient, pre-dialysis urea will
remain low in spite of inadequate dialysis; this may incorrectly
instigate a decrease in the dialysis quantity. Concentration
parameters as an index of toxin elimination are to be considered
as unsuitable indices [75]. In a study by Degoulet et al, low urea
corresponded to a high mortality risk [74]. In parallel, Oksa,
Pasternack and Pasanen demonstrated that survival was higher
for a low urealcreatinine [76]. In an elegant logistic regression,
Lowrie and Lew demonstrated that low serum albumin and low
serum creatinine, not high, were associated with a high death
risk [77]. All these findings refute the general belief that bad
outcome is only found at high pre-dialysis serum solute con-
centrations.
Dynamic biochemical tests. (1.) Percentage removal (Table
5, equation [1]). Percentage removal, pre- versus post-dialysis,
is an index of solute elimination during dialysis, and inversely,
of solute gain between dialyses. It does not take into account
complex kinetic behavior, and should therefore be considered
as an approximation. This parameter is related to more sophis-
ticated kinetic parameters, such as KtIV for urea [78, 79].
(2.) Clearance. Clearance can be defined as the volume of
blood that is purified per unit of time, which depends both on
diffusion and convection. Higher clearance equals principally
better adequacy. (2.a.) Blood compartment clearance. Clear-
ance is calculated based on blood flow (Q) determinations and
concentrations in blood samples collected from the inlet and
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Table 3. Clinical signs that may reflect underdialysis Table 4. Static biochemical parameters used in the assessment of
dialysis adequacyNervous system
Stupor, coma Non-retention products
Polyneuritis Hematocrit
Convulsions Red blood cell count
Fatigue Thrombocyte count
Motor weakness Coagulation tests
Concentration disturbances Total protein
Insomnia Albumin
Headache Transferrin
Irritability Parathormone
Reduced sociability pH
Restless legs Bicarbonate
Cramps Cholesterol
Tics Triglycerides
Electro-encephalographic changes Immunoglobulins
Electro-myographic changes
Gastrointestinal system Retention productsUreaHiccup CreatinineStomatitis
Parotitis j32-microglobulin
Pancreatitis PhosphatePotassiumGastritis
Colitis Uric acidHippuric acidUlceration ______________________________________________________________________
Anorexia
Nausea
Vomiting
Hematological system [80]. QB can most readily be estimated by injecting an air bubble
Anemia into a disposable additional track of known cross sectional area
Bleeding and length; the measured transit time over a known length
Immune system yields a reliable blood flow calculation. The use of photo-Susceptibility to infection
electric cells may reduce observer error [81]. An alternative isCancer
Decreased response at vaccination the electromagnetic flow probe, but this approach necessitates
Skin anergy frequent calibration and sterilization.
Cardiovascular system Ultrafiltration adds extra solute flux to diffusion, so that
Pericarditis elimination is increased by a quantity that does not matchHypertension, hypotension
Atheromatosis ultrafiltration rate (QF) (Table 5, equation [3]) [82], Its negative
Cardiomyopathy impact on diffusive clearance was first recognized in coil
Edema dialyzers [83], but appeared later to be present for all types of
Increased cardiothoracic index dialyzers [84], and should always be considered for the calcu-Skin
Pruritus lation of QB-based clearances. The additional clearance deliv-
Melanosis ered by ultrafiltration equals ultrafiltration, multiplied by 100%
Defective wound healing minus percentage removal: the greater the diffusive removal,
Endocrinology the less is the impact of ultrafiltrative removal (and vice versa;
Glucose intolerance Fig. 4).Growth retardation
Hyperparathyroidism Recirculation occurs when dialyzed blood is recycled
Hyperlipidemia through the dialyzer inlet. It is considered to be a typical
Hypogonadism drawback of single needle (SN) dialysis, but is as well present in
Impotence two needle dialysis, especially high efficiency dialysis [85, 86],Diminished libido
Bone disease whereby blood flow and recirculation are related. Enhancing
Osteodystrophy, osteomalacia conditions are: (1) high dialyzer blood flows, (2) vascular access
Amyloidosis inflows lower than dialyzer blood flow, (3) stenoses at the
Nutritional status access outflow, (4) common or close in- and outlet vascular
Weight loss pathways, (5) increased length of blood lines, (6) increasedWasting
Miscellaneous compliance of dialyzer outflow, (7) incorrect position of the
Thirst needle in the AV-fistula, (8) small stroke volumes (in single
Hypothermia needle dialysis), (9) small needle and tubing diameter. The
Foetor impact of recirculation on clearance is formulated in Table 5,Exercise intolerance
Ascites equations [4] and [5].
The nonhomogeneity of blood may hinder solute removal by
imposing a slower transport from blood cells to blood water
outlet blood lines (Table 5, equation [2]). Several influencing than from blood water to dialysate. This necessitates erythro-
factors should be considered: cyte equilibration with plasma [87], and/or cell lysis [88], before
The error in blood flow determinations may be substantial determination of concentration to calculate blood clearance, or
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Table 5. Most current equations used in the calculation of dialytic
solute elimination
Percentage removal:
R,, = [1 — (Cpre — Cpot/Cpre)1 * 100
Blood compartment clearance:
KB = QB * [(C, — C0)/C1]
Clearance corrected for ultrafiltration:
KF = [(C1 — C01C1) * (Q — QF)] + (Q,,)
Recirculation:
R = (C,, — C,)I(C,, — C0)
Clearance corrected for recirculation:
KR = [(1 — R) * KF]/[l — R * (1 — KFIQB)
Dialysate clearance:
KD = (CD * VD)ICMB
Clearance based on distribution volume:
= lfl(Cpost/Cpr) * V/T
Urea kinetics:a
G = KR[Cpr2 — C,,01, * exp(—KR * O/V)I
1 — exp(—KR * OIV)]
V =
—K. * TIln[C,,012 — GIKT)I(Cpre2 — G/KT)I
PCR from G:
PCR = (G + 1.7)10.154
Symbols and abbreviations are: C, concentration dialysate; C,,
concentration dialyzer inlet (blood compartment); CMB, mean concen-
tration in blood (pre- vs. post-dialysis); C0, concentration dialyzer
outlet (blood compartment); C,,, concentration peripheral blood; Cpre,
concentration pre-dialysis; C,,01, concentration post-dialysis; G, gener-
ation per minute; G, generation per 24 hrs; KB, blood compartment
clearance; KD, dialysate clearance; KF, clearance corrected for ultrafil-
tration; KR, clearance corrected for recirculation; KR, residual clear-
ance; KT, total clearance (residual + dialyzerclearance); K, clearance
based on distribution volume; PCR, protein catabolic rate; R, recircu-
lation; R,,, percentage removal; QB' dialyzer blood flow; QF' ultrafil-
tration rate; T, dialysis time; 0, interdialytic time interval; V, distribu-
tion volume; V, volume dialysate.
The subscripts 1 and 2 refer to the 1St and 2nd dialysis of a weekly
cycle
determination of plasma clearances after immediate processing
and before re-equilibration [891. Even for urea, an isolated
report suggests resistance of the red cell membrane, causing
disequilibrium [90]. A later study excluded such a disequilib-
rium [91] conforming with cell wall mass transfer coefficients in
the range of 700 ml/min [9], which is substantially higher than
the current dialyzer clearances. Blood clearances are then as
reliable as plasma clearances, and immediate processing is not
necessary. These rules do not necessarily apply for other
solutes than urea.
A mass ratio between red blood cells and plasma of has
been reported for urea, which acknowledges that respective
plasma and erythrocyte water contents are 93 and 79% [80].
In summary, blood side clearances are subjected to important
flaws, which necessitates correct blood flow and concentration
measurements, and correction for recirculation and ultrafiltra-
tion, protein binding and RBC/plasma disequilibrium [87]. Most
errors will result in an overestimation of clearance and create a
(8)
(9) 0 20 40 60 80 100
Ultrafiltration rate, mi/mm
(10) Fig. 4. Increase in clearance when ultrafiltration (convection) is addedto diffusive clearance. Symbols are % removal: (*. . . *) 30%; (x----x)
50%; (• •) 70%. The increase obtained equals ultrafiltration multi-
plied by the difference between 100% and percentage removal [QF *
(100% — PR)] where percentage removal pre- vs. post-dialysis equals
PR = [(C1 — C0)1C1) * 100]. The increase in clearance is more important
as percentage removal is lower, but is always smaller than ultrafiltration
per Se.
false feeling of security. Even if determined cautiously, it is
suggested to match blood side clearances to simultaneous
dialysate clearances [14, 92].
(2.b.) Dialysate clearance. The principle is the same as for
genuine "urinary" renal clearance: collection of all dialysate
and calculation of total solute waste (Table 5, equation [6]).
Calculations of mean pre- and post-dialysis values may result in
an underestimation of clearance, as a linear decay of blood
solute concentration is presumed. Further error sources are low
dialysate concentrations and incorrect determinations of dialy-
sate volume. Specific devices that collect small timed aliquots
of dialysate may be less cumbersome than large graduated tanks
[93]. Dialysate clearance, by its concept, is not subject to the
vagaries of Q, determination, ultrafiltration or recirculation
[94]. Unbalance between dialysate clearance and blood clear-
ance may, however, occur as a consequence of membrane
binding of solutes: this will induce mass balance error and an
underestimation of clearance when estimated from dialysate.
(2.c.) Clearance based on distribution volume. Based on first
order kinetic principles, this calculation multiplies the ratio of
single pool distribution volume (V) over dialysis time with the
negative natural logarithm of the ratio concentration pre/post-
dialysis (Table 5, equation 7) [95, 96]. The source of error with
this approach is minimal and depends on only two factors,
concentration and distribution volume. This approach can be
80
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a)C)C
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(4) 40
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C
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J
(6) 20
(7)
///+
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I I0
used for the determination of urea clearance. ure may be
estimated from its distribution over body water, which, how-
ever, occupies a variable fraction of body weight (Fig. 5) [97].
In addition, urea distribution volume does not always concur
with body water. The current trend of considering Vurea as 58%
of total body weight is thus a source of error. The use of
morphometric data may result in more reliable calculations
[98—101], although those data are currently based on non-
uremic subjects. Exact estimations of Vurea can only be ob-
tained by injection of radioactive urea, or by the use of multiple
pool models.
In conclusion, clearance values based on pre- and post-
dialysis concentrations and distribution volume, will give ac-
ceptable results, as far as the approximation of V is reliable.
Whatever the method, the clearance approach estimates solute
elimination in function of the dialyzer and the dialysis tech-
nique, but does not take into account patient (body size), solute
(generation) and/or kinetic characteristics (protein binding, cell
membrane transport).
(3.) Kinetic modeling. (3.a.) Single pooi kinetics. Single pool
models relate to small water soluble compounds, with equal
distribution. Distribution volume (V) and generation (G) are
interactive and are calculated by iteration from intra- and
interdialytic shifts 1102]. The single pool model assumes: (1)
instantaneous mixing without shifts within the pool; (2) con-
stant generation; (3) constant rate of interdialytic weight gain.
These assumptions are correct only by approximation.
(3.b.) Urea kinetic modeling. The current urea model ac-
knowledges zero-order (that is, linear and constant) generation
and first order (proportional to concentration) removal, based
on single-pool distribution over body water (Table 5, equations
(8] and [9]) [96, 103, 104]. The evaluation of this model in the
U.S. National Cooperative Dialysis Study (NCDS) was a major
impetus for its use [105]. Clinical evaluation showed a lower
morbidity in patients with kinetic parameters within the follow-
ing boundaries: (1) time averaged concentration of urea
(TACurea) expressed in BUN of mg/dl; (2) protein catabolic
rate (PCR) from 0.8 to 1.4 glkg body wt 24 hrs; and (3) total
clearance over distribution volume (KtIV) >0.8 [57, 106].
Primarily cardiovascular, gastrointestinal, and infectious com-
plications influenced morbidity (Table 6) [107, 108], but not
mortality. When patients returned to their conventional treat-
Table 6. Significant differential findings of the NCDS study
Percent body fat and muscle circumference: lower in group with low
urea generation.
Depression scores: lower in the group with highly efficient shorter
dialysis.
EEG spectral analysis: more deterioration in high BUN groups.
Sleep abnormalities: in group IV (high BUN, short dialysis).
Muscle cramps, concentration disturbances, fatigue, anorexia,
headache, dyspnea: more in high BUN groups.
Hematocrit and transfusion requirement: respectively lower and
higher in high BUN groups.
Potassium, anion gap, phosphate, parathormone: higher in high BUN
groups.
Cardiovascular morbidity: higher in high BUN groups.
Hospitalization requirement: higher in high BUN groups.
Data are extracted from 1O7J, Used with permission.
ment, however, significantly more deaths occurred in the high
TACurea groups. The effects of inadequate dialysis may thus
persist, even after return to a more efficient regimen.
Tacurea is increased by generation and decreased by elimina-
tion. This valuable kinetic parameter [108—1101 does not discern
among influencing factor(s), so two other parameters (PCR and
Kt/V) were introduced. Swings in concentration are not per-
ceived.
Urea kinetics offer an index of metabolic status, urea gener-
ation, that is directly correlated to the protein catabolic rate
(PCR) (Table 5, equation [10]) [111]. The important entero-
hepatic circulation of urea in uremia [112], as well as losses via
skin, sweat and breath are ignored. Note that this correlation
between generation and PCR is based on data obtained in only
five patients [111]; a virtually identical regression line was
observed by Cottini, Gallina and Dominguez in non-dialyzed
chronic renal failure patients [113]. In equilibrated patients PCR
is considered as a parameter of protein intake (P1). PCR is also
correlated to potassium and phosphate intake [105], although
these relationships do not necessarily imply protein as the
source. As protein breakdown is a source of proton, it may also
be related to uremic acidosis. A strong correlation between
546 Vanholder and Ringoir: Adequacy of dialysis
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Fig. 5. Distribution volume of water (V),
expressed as percentage of body weight, and
calculated according to anthropometric
equations (ref 99), based on sex, body weight
and length. Extreme variations are observed.
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Kt/V and protein intake has been demonstrated [114, 115],
which would mean that inadequate clearance results in inade-
quate food intake (or vice versa), were it not that the formulae
to calculate these two parameters are mathematically related,
that is, they are partly based on the same or similar terms.
The NCDS calculation of PCR discloses that only 25% of
patients need dietary interaction [104]. The kinetic approach
thus liberates time for assistance by dieticians only where it is
needed. A major fraction of these patients are, however,
resistant to dietary manipulation [106] and many of those are
aged [116]. Low protein intake results in low energy metabolism
and wasting [117] if not compensated [118]. PCR is unreliable as
an index of protein intake in overt catabolic or anabolic states
[119], arousing some questions about its validity as an ubiqui-
tous index of P1.
It is advised to prescribe levels of Kt/V above 0.8 to 1.0 [105],
except for rapid high efficiency dialysis, where values above 1.2
are pursued. Note that Kt/V> 1.0 was already proposed in 1978
by Ginn et al, when they recognized the necessity to deliver a
clearance of at least 3000 ml/kg week in three dialysis sessions
to maintain satisfactory clinical condition [120].
To stop dialysis once one urea distribution volume has been
cleared, has been arbitrarily set; healthy kidneys clear much
more in 48 hours than one urea distribution volume. Keshaviah
and Collins, reconsidering the NCDS database, claim that
morbidity linearly declines as Kt/V increases, and that there is
no optimum Kt/V [121]. In analogy, Shen and Hsu found a
hospitalization rate to be inversely proportional to Kt/V [1221.
With an iterative kinetic model, calculations of Kt/V and
even of PCR will result in uniform values, irrespective of the
clearances whereupon the calculation is based, as V is calcu-
lated from clearance and vice versa [80, 100, 101, 123]. Several
simplifications to calculate Kt/V have been proposed [78, 79,
124—128]. Errors may be in acceptable range for clinical pur-
poses [781, but most of these approaches give no suggestion
about PCR.
(3.c.) Pitfalls of the current urea kinetic determinations.
Incomplete delivery of dialysis prescription [129] induces, when
not recognized, flaws in kinetic calculation. Errors in registra-
tion of dialysis time due to connection, disconnection, turning
down of blood flow and interruptions, manufacturer clearances
that overestimate true clearance, dialysis devices that overes-
timate true blood flow, and lack of correction for recirculation,
all will result in a misconception of dialysis dose, and hence of
G and V [130—132].
PCR diverges from PT estimated by dietary anamnesis (Fig. 6)
[104, 133]. The assumed cause is that outpatient food-intake
records are of limited value [134]. Patients may overestimate a
low food intake and vice versa. Imbalance may, however, also
be due to the unsuspected presence of catabolism or anabolism
[133]. Controls in metabolic wards of the reliability of PCR as
an index of P1 are scant [135]. Protein intake may further differ
from day to day. Therefore, the reliability of PCR as an index of
P1 may be debated at least under certain conditions.
TACurea and PCR, although both significant predictors of the
failure of dialysis, account for only 14% of the difference in
failure rates in the NCDS. Only groups with a TACurea in the
range of SO (low TAC) and 70 (high TAC) were enclosed,
whereas PCR was maintained between 0.8 and 1.4 g/kg day.
Patients with a low PCR automatically have low Kt/V, so that
both parameters are dependent: although the NCDS claims that
a PCR below 0.8 g/kg . day carries a higher morbidity, most
patients also have a Kt/V below 0.8, making it unclear which
factor is responsible. Reanalysis of the NCDS shows that PCR
< 0.8 g/kg body wt day may be a poor predictor of failure
[121].
The NCDS was limited to small pore cellulosic dialyzers, that
are incompatible versus the complement-leukocyte system
[136, 137] and possibly have a catabolic effect [138]. Later
introduced dialyzers with larger pores and a better compatibil-
ity may require a lower delivery of urea clearance and/or PCR
than cuprophane [114].
Asymmetry in protein intake, dialysis efficacy and/or dialysis
schedule may render kinetic results unreliable [139]. Gross
changes (infection, pericarditis, fluid overload) may require
larger increases in dialysis quantity than those proposed by the
NCDS in mostly well equilibrated patients.
(3.d.) Multiple pool models. Many solutes and potential
uremic toxins distribute over several pools: substances with a
slow transport from intra- to extracellular, protein binding,
and/or a middle to high molecular weight, such as peptides [140]
or guanidines [141]. The site of generation may affect concen-
tration, both in the cell and in the plasma [91, especially when
the cell membrane restricts transport. When metabolite is
generated in one small well perfused specialized organ (for
example the liver for urea), generation can be considered to be
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Fig. 6. Correlation-regression between protein intake, determined by
dietary anamnesis, and protein catabolic rate, calculated from urea
kinetics, is absent (simultaneous determinations in 46 patients, r =
0.257, P > 0.05). In those with a low PCR, anamnestic Fl is often high,
and vice versa.
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Table 7. Dialysis strategies and their influence on solute removal
Small, water Small, protein
soluble bound Large
Conventional hemodialysis
Small pore dialyzers + + — —
Large pore dialyzers + + + +
Single needle dialysis
Small pore dialyzers + ÷
Large pore dialyzers + + + + + +
Hemofiltration
Hemodiafiltration + ÷ + + + +
CAVH
CAPD + ++ ++
Short dialysis
Small pore dialyzers + — —
Large pore dialyzers + + + + +
Symbols for removal are: + +, strong; +, present; moderate; —,
minimal or absent.
Time, minutes
Fig. 7. Intra-dialytic evolution of urea at 30 minute intervals (squares)
is more accurately described by a two pool than by a single pooi kinetic
model (———).
extracellular. Multiple pool models for the study of dialysis
have been reported repeatedly [9, 90, 142—146]. According to
Popovich et al, the use of more than two pools may add little
accuracy [145].
Multiple pool models can predict changes in body compart-
ments normally inaccessible to the clinician [91. Since toxicity
will mainly affect intracellular systems, it may be clinically
more relevant to focus on predicted intracellular or intratissular
concentrations, rather than on plasma concentrations, accord-
ing to the concept of the biologically-active distribution volume.
Two pool models should thus not be discarded as overly
complex, as they may disclose important new information.
Even the intradialytic behavior of urea is better described by
a multiple than by a one compartment model [147] (Fig. 7),
whereby transcapillary exchange between intravascular and
slow equilibrating interstitial fluid spaces may be the rate
limiting step [148, 149]. The multiple pooi distribution of urea is
also supported in non-uremic non-dialysis models [148, 150,
151], Matthews and Downey demonstrated that both pools are
nearly equal in volume, and much larger than the intravascular
volume of a normal adult [1511. They postulated that the urea of
the blood rapidly mixes with intracellular water of well-per-
fused organs, whereas it mixes more slowly with poorly per-
fused organs and interstitial water. If an exact scientific ap-
proach of the intradialytic behavior of urea is to be pursued, a
two pool model may thus be more appropriate. A single pool
model is more attractive for routine clinical conditions, because
of its easy applicability.
A phenomenon related to the two compartment behavior of
urea is the post-dialysis rebound that is especially observed
with short high efficiency dialysis [152]. The urea rebound may
not be caused exclusively by transtissular disequilibrium, but
may be affected by an increase in protein catabolism [1531
induced by loss of amino acids and glucose [111, 142], and/or a
catabolic effect induced by blood contact with the dialysis
membrane [138]. Lim and Flanigan showed in patients on a
constant protein diet a decrease in PCR when interdialytic
intervals were increased from two to three days, which suggests
a catabolic effect of dialysis [154]. The occurrence of urea
rebound, even with radiolabeled exogenous urea, however,
suggests that a multicompartmental behavior with disequilib-
rium is the major factor inducing rebound [131, 147].
Disequilibrium may by itself cause major uremic symptom-
atology, mainly encephalopathy, due to osmotic shifts [155],
although urea may not be the responsible solute [156]. It can be
prevented by administration of extra osmoles (glucose, manni-
tol) [157]. Curiously enough, the disequilibrium syndrome is
less frequent today, in spite of a generalized increase in dialyzer
efficiency.
Conclusion
Several strategies estimate dialysis adequacy and/or uremic
toxicity. All of them are subject to flaws and criticism. Clinical
parameters take into account the patient's condition, but are
partly subjective, and may only be perceived when gross
changes occur, when it is too late. Purely objective parameters,
based on biochemical determinations, may disregard the clini-
cal condition. Kinetic modeling, taking into account both pa-
tient and dialysis related factors, is perhaps the most com-
pletely objective method, but has up to now only been applied
on a regular basis for urea, that may not match with all
conditions required from the ideal marker (see below). The
sources of error are multiple, so that a multifactor approach,
also taking into account clinical condition and static biochemi-
cal parameters, is still to be preferred, until more reliable
markers of uremia become available.
Influence on solute removal
Conventional hemodialysis
Solute transport is mainly by diffusion, and essentially of
small compounds, except when dialysis time or pore size are
increased (Table 7).
Hemofiltration/hemodiafiliration
In hemofiltration large quantities of ultrafiltrate are substi-
tuted by a saline electrolyte solution. Solute is eliminated by
convection [158]. Large pore dialyzers with high permeability
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result in a clearance rate plotted against molecular weight
similar to that of the native glomeruli [159]. The active transport
mechanisms of the tubule are mimicked only in part. Elimina-
tion of small compounds is difficult, except with exchange
quantities more than 15 to 18 liters per 24 hours. Schaeffer et al
demonstrated a higher survival for patients older than 60 years
on hemofiltration, compared to patients on conventional dialy-
sis [160]. This suggestion awaits confirmation in less selected
patient groups.
In hemodiafiltration and in paired filtration dialysis, diffusive
dialysis is combined to an extra ultrafiltration of 10 liters or
more, with substitution, which achieves better removal of small
and large molecules than hemofiltration and hemodialysis,
respectively [20, 89, 161—166]. Clearance may be lost to the end
of the session, due to protein deposits on the membrane [84].
Maybe surprisingly, the gain in efficiency made available by
these strategies, has mainly been used to reduce dialysis time,
and not to improve removal.
Continuous arteriovenous hemofiltration
The principle is the same as for hemofiltration, but the
process is continuous at low blood flows, driven by blood
pressure [167—168] or pumps [1691. Solute elimination may be
insufficient for small water soluble compounds, which can be
corrected by the continuous or intermittent use of dialysate
(CAVHD, continuous arteriovenous hemodialysis) [170].
Continuous ambulatory peritoneal dialysis
With the peritoneal membrane as a semipermeable barrier,
the principles of diffusion and convection are the same as in
hemodialysis. Differences in small solute clearances between
both strategies can be attributed to differences in dialysate flow
[171]. CAPD becomes more effective than hemodialysis as
molecular weight increases [7, 172], which has been used as an
explanation for good clinical condition in CAPD patients in
spite of lower urea elimination [173, 1741. Disequilibrium, if
any, will be lower due to the continuous low-efficiency aspect of
CAPD [172]. Residual renal function remains better preserved
with CAPD [175], which may add to efficiency, and contribute
substantially to Kt/V, especially early after the start of renal
replacement [176]. One can only speculate about the mecha-
nisms involved in this preservation of residual renal function:
CAPD may (1) remove toxic factors that are involved in
nephron destruction; (2) preserve or enhance growth factors
involved in a beneficial effect on GFR; or (3) simply cause less
harm to renal function due to a more stable hemodynamic
status.
Short dialysis
With advanced technology, it became possible to reduce
dialysis time [177—179]. Encouraging clinical results may be
attributed to efficiency control, a better elimination of larger
molecules, and/or the use of more biocompatible membranes.
Patients on short but efficient dialysis schedules display signif-
icantly lower depression scores [107].
Caution against short dialysis [33, 180—182] has in general
been based on out-of-date dialysis strategies and obsolete
parameters of adequacy, although in a French center excellent
survivals and low morbidities were obtained over many years
with a 24 to 30 hr/week regimen with standard Kiil dialyzers
[183, 184]. Follow-up occurred in a low-risk population [185].
Shortening dialysis without scrutinous control of the clinical
condition and solute elimination may have deleterious conse-
quences [186]. Decrease in dialysis time should be compensated
by a more than proportionate increase in elimination [187].
There is less margin of safety in case delivered and prescribed
dialysis would not match. Uncontrolled shortening of dialysis is
one of the proposed explanations for the recent increase of
mortality in the USA [68, 77, 129, 188—192]. These data prompt
to a critical evaluation by objective parameters of efficacy [193].
Single needle or single catheter dialysis
Single needle dialysis (SND) creates access through one
vascular pathway [194]. At least with pressure-pressure con-
trolled systems, it is possible to obtain similar small solute
kinetics as with current two needle strategies [195]. In addition,
the fluctuating flow pattern may allow a better elimination of
larger molecules than for the current two needle approaches
[196].
Single needle or single catheter dialysis reduces fistula dam-
age, allows ultrafiltration control and adaptation to diverse
strategies including single lumen central catheters [196—198]. A
mean blood flow in the range of 250 to 280 mi/mm can easily be
obtained. Higher blood flows enhance the risk for hemolysis
[199], making short high-efficiency dialysis difficult to achieve
with SND. The mathematical yearly 50% decrease in use of
needles or puncture sites should reduce the risk for vascular
damage or for accidental needle punctures with possibility for
transmission of AIDS and other infectious diseases. SND could
mean a protection for both staff and fellow patients in those
units confronted with a frequent incidence of AIDS.
Dialyzer reuse
Fiber bundle loss due to obstruction by clotting [200] corre-
lates to dialysance [201—203]. Dialyzers are currently discarded
at a volume loss of 20%, which corresponds to a clearance
decrease by 10%. Then no substantial changes in vivo dialy-
sance are registered [204]. These rules have been set for
cuprophane dialyzers but are not necessarily the same for other
membrane types, where efficacy losses may occur in spite of
acceptable volume tests, whereas differences in behavior may
also be related to the nature of the sterilant [205, 206]. Reuse
may alter flow distribution of dialysate, which goes unrecog-
nized by the current quality control validation tests [207].
Conclusion
Various degrees and types of solute elimination can be
pursued by applying various dialysis strategies. The strict
allowable minimum can be pursued by conventional hemodial-
ysis, resulting mainly in elimination of small, water soluble
compounds, such as urea, when respecting the limits imposed
by the NCDS. Most other strategies allow additional elimina-
tion of other compounds with a more complex kinetic behavior
than urea. The toxicity of these compounds, and their validity
as markers, will be discussed in the next section, but remain a
matter of debate. In general, one may presume that pursuing
elimination of more solutes than proposed by the NCDS may
decrease toxicity. Whether this will affect life quality and
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survival urgently needs to be answered by prospective, multi-
center studies.
The ideal marker
The ideal marker of adequacy could be defined as: (1)
retained in renal failure; (2) eliminated by dialysis; (3) with
proven toxicity; (4) generation and elimination representative
for other (preferably toxic) solutes; (5) concentration related to
clinical outcome; (6) easily determined. No current marker
matches with all these conditions.
Urea
The toxicity of urea is minimal [102, 2081, except at concen-
trations that exceed those currently encountered in dialyzed
patients [209—211]. Its generation is representative for protein
breakdown, and gives an indication of metabolic status. How-
ever, its removal by dialysis is not necessarily representative
for the other protein breakdown products [140], whereas not all
uremic solutes result from protein breakdown. Several toxins
show an elimination pattern that is different from urea [140, 141,
208, 212, 2131, especially during dialysis with open membranes
[164, 213]. Blumenkrantz et a! successfully induced anabolism
in CAPD patients by administering a 1.4 g/kg body wt protein
diet, in spite of a BUN far above the NCDS ideal values [2141,
casting doubts on the validity of urea as a marker of uremic
toxicity. A similar dissociation between blood urea and meta-
bolic status was observed in CAPD with dialysate containing
amino acids [215]. Recently, Blake et al showed no correlation
between urea kinetic parameters in CAPD patients and clinical
outcome [115].
The toxic role of urea has been overemphasized, probably
due to its abundance and ease of measurement. However, it is
hard to believe that the whole array of non-water soluble, large,
and/or protein bound solutes would be of no importance in
"uremic" toxicity. Many of the latter have been demonstrated
to exert toxic effects on biochemical and biological systems. In
contrast, only few studies demonstrate a toxic effect of urea in
the concentrations currently encountered in end-stage renal
disease. This does not exclude, of course, the toxicity of other
water soluble compounds (such as potassium).
Middle molecules
Middle molecules are intangible compounds with a molecular
weight between 300 and 5,000 Daltons [216], that may interfere
with peripheral nerve function [19, 217, 218], although well
controlled toxicology studies are lacking. Middle molecular
peaks are prominent in severe uremia [219]. Their pathophysi-
ologic importance has been debated [220, 221]. In the mid-
seventies, dialysis strategy was structured around their hypoth-
esized kinetic behavior [222], resulting in the square meter hour
hypothesis [19] and the dialysis index (D1). Those express
middle molecule removal as an area-time dependent, that is,
flow independent elimination [2171, although the presumed
two-pool kinetics of middle molecules led Popovich et al [145]
to conclude that the square meter hour hypothesis was invalid.
The minimum numerical value for D1 for each patient arbitrarily
was set at 1.0, but calculation was based on in vitro data and on
a non-uremic marker hypothetically corresponding to the pre-
sumed middle molecules or range of these molecules: vitamin
B12 (molecular wt: 1353 D).
Table 8. Hippuric acid sources and toxicity
Sources
Quinic acid:
in fruits (prunes and cranberries)
in tea
Sodium benzoate, as a preservative
in beverages, jams, jellies, conserves
in deep frozen preparations
Phenyl containing fatty acids
Phenylalanine
Toluenes (environmental)
Benzyl alcohol (in some brands of heparin)
Production by intestinal flora
Potential toxicity
Interference with organic acid transport
in renal tubule
in other transport systems (such as, chorioid plexus, ciliary
body, thyroid, liver, erythrocytes)
Decrease drug protein binding
Decrease glucose tolerance
Decrease platelet cyclo-oxygenase activity
Decrease erythroid growth
Correlation to polyneuropathy
The major problem was thus the lack of well defined repre-
sentative solutes of middle molecular range. With improved
analytical techniques, it became evident that presumed middle
molecular fractions are in fact heterogenous mixtures contain-
ing many lower molecular weight compounds [208, 216, 223],
which extends the definition of middle molecules to the smaller
molecules with protein binding and/or multicompartmental dis-
tribution.
There are several biochemical arguments that support toxic-
ity for molecules corresponding to this definition [224—235].
Failure of the early peritoneal dialysis patients to develop
neuropathy suggested that the peritoneum is more permeable to
larger molecules than hemodialysis membranes [219]. In at least
10 studies, reduction of urea elimination, coupled to an un-
changed or enhanced "middle molecule" removal, caused no
deterioration of clinical condition [236—247]. Most studies were,
however, uncontrolled, in small patient groups, and over short
periods. These data underscore the need for a larger multicenter
study, where in parallel to the NCDS the impact on morbidity
and mortality is evaluated with a better differentiation between
small versus larger molecule elimination. Note that in the
NCDS, length of dialysis, which is related to middle molecule
elimination, had a significant effect on morbidity within the high
TACurea groups. On this basis, Lindsay and Henderson recom-
mended to choose a membrane that gives the highest clearances
in the larger, as well as in the low molecular weight range [248].
Hippuric acid
Hippuric acid (molecular wt 179 D) behaves like a larger
molecule, due to protein binding, that even increases during
dialysis [249, 250]. It can easily be determined by colorimetnc
methods as well as by HPLC [251, 252]. Generation is depen-
dent on multiple factors [249] (Table 8). It exerts toxic activity
on several metabolic processes [225, 227, 233, 253—260] (Table
8), and its behavior may represent toxic organic acid like
compounds that are excreted by renal tubules [213]. Data about
a relation of concentration to morbidity or mortality are lacking
at this time.
Vanholder and Ringoir: Adequacy of dialysis 551
Parathormone
Concentration of parathormone (PTH), a large molecule with
proven toxicity [261], results from a number of compensatory
mechanisms (trade off), rather than accumulation. Elimination
by dialysis is not critical [262], except with some membranes,
such as polyacrylonitrile that mainly adsorb PTH [2621. The
long run PTH concentration is, however, not necessarily af-
fected, even not with hemo(dia)filtration [166]. Serum PTH is
an indirect parameter of chronic inadequate dialysis, since its
production follows phosphate accumulation.
12Mtcrogbo1,dmn
/32-microglobulin (f32m, molecular wt 11,600 D) appears in the
extracellular fluid, by "shedding" [263]. A substantial amount
is eliminated via residual renal function. /32m distributes as an
unbound monomer in two body water compartments, plasma
and interstitial fluid [92]. It is not clear whether generation per
individual is constant, or whether there is some feedback
mechanism. Its toxicity is related to the development of dialy-
sis-related amyloidosis [264]. Hemodialysis with cuprophane
containing dialyzers results in a rise in f32m concentration [265],
which is related to hemoconcentration without elimination [31,
49]. Correction for changes in extracellular volume demon-
strates that the true /32-microglobulin pool does not change
substantially during this type of dialysis [49, 266]. Elimination is
more pronounced during dialysis with high flux dialyzers [32,
267]. Even when strategies with an important f32m removal are
used, serum levels remain unaltered over long periods [268,
2691. Nevertheless, van Ypersele de Strihou et al demonstrated
that patients treated solely by open AN69 membranes displayed
less frequently signs of bone amyloidosis than those treated by
cellulosic membranes [270], but it is not clear whether these
results should be attributed either to better elimination or to
lower generation in the context of better biocompatibility.
Phosphorus
Phosphorus concentration is the result of protein catabolism
and protein intake, but also of extra dietary phosphate sources
(assorted meat products, cabbages, etc.). Intra-dialytic evolu-
tion is not straightforward and is not comparable to that of urea,
creatinine or uric acid [2711. Dialytic removal is followed by a
marked rebound [272], even during dialysis [271]. There is no
direct correlation with urea elimination. As a marker, its
behavior is too specific, and not directly representative for
other compounds.
Conclusion
In general, none of the current markers of dialysis adequacy
and uremic retention are satisfactory. A combination of several
marker systems, together with clinical information, should
therefore be preferred as of today.
Future perspectives
There is no ideal marker nor formula for dialysis adequacy.
Apart from urea, there is no solute for which concentration has
been correlated to outcome. Therefore, we suggest that an
optimal urea removal should be pursued as a primary goal. On
the other hand, there is more than urea, and urea per se is not
or only moderately toxic. Optimum elimination of other corn-
pounds, such as 132-microglobulin or hippurate, may be of
additional help. The problem is that we have no exact rules as
to the concentration to be pursued for the latter compounds.
Dialytic removal remains aspecific, whereby toxic as well as
indispensable compounds are eliminated indiscriminately.
Quoting L.W. Bluemle back in 1967: "It is reasonable to expect
that additional information about the mechanism of uremia can
be gained from additional studies on animal and on uremic man,
which hopefully may lead to the generation of new hypoth-
eses of disturbed metabolic pathways." We are convinced that
this statement still holds at the present time, 25 years later.
Today we may know more than a quarter of a century ago, but
our knowledge remains too fragmentary.
A more directed approach necessitates a better definition of
uremic toxicity. If the different biochemic mechanisms of the
uremic syndrome were better defined together with the respec-
tive responsible compounds, selective elimination by adsorp-
tion devices could be pursued [273]. Experiments to use ad-
sorptive charcoal in urernics have been abandoned because of
its deficient elimination of urea. On the other hand, organic
acids are adsorbed to a high degree by charcoal [274]. In our
opinion, the combination of hemodialysis with charcoal adsorp-
tion [275] should be reconsidered. Medicinal adsorption in the
gastrointestinal tract remains another alternative [276]. More
specific adsorption may be pursued by the use of enzymes
and/or antibodies, but binding may be weak or saturation fast,
and subjected to aspecific competition as seen with protein
binding of drugs or solutes.
With urea kinetics as the mainstay of adequacy estimation,
these kinetics should be more correctly defined. The current
single pooi model is a mere simplification. Further attempts to
simplify are probably useless. Continuous follow-up of blood
urea nitrogen (by a urea biosensor) or repeated intra-dialytic
urea measurements (by dry chemistry) may increase the possi-
bilities to model urea continuously based on a more appropriate
two-pool model.
Alternative markers other than urea should be considered
whereby the disgraced "middle molecules" should not be
disregarded. They compose a large group of retained solutes
with potential toxicity. Hippuric acid and/or f32-microglobulin
are candidate marker molecules in this group. Large multi-
center efforts (in analogy to the NCDS for urea) are needed to
define the clinical effect of differences in concentration of these
markers and the ideal concentrations and removal rates to be
pursued. Alternative markers may make their appearance as
our knowledge of the uremic syndrome increases.
It is obvious that the interactions during dialysis between
foreign material and patient (so-called bioincornpatibility prob-
lems) will influence clinical condition as well as dialyzer surface
structure, with either direct or indirect implications on dialysis
adequacy. Improving biocompatibility will improve adequacy
of dialysis. The authors are aware of the importance of this
issue but considered the topic beyond the scope of the present
review, because it would increase the length of the paper
considerably. The reader is referred to specific reviews on this
topic [277, 278].
An excellent clinical condition and general status of the
uremic patient remains in fact the ultimate goal of adequate
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dialysis, but the definition of normal or healthy in this context
continues to be one of the most difficult and subjective areas in
nephrology.
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